Imricor Medical Systems Inc (ASX:IMR)

Imricor Medical Systems Inc reported its financial results for the second quarter ending June 30, 2026, showing a net loss of $7.38 million, which is slightly lower than the $7.80 million loss in the same quarter of the previous year. The company experienced a decrease in revenues to $60,531 from $65,163 in the same period last year. Despite the decrease in revenues, total assets increased to $73.59 million from $45.76 million at the end of 2025, driven by a significant rise in cash and cash equivalents. Operating expenses increased due to higher costs in research and development, sales and marketing, and general administrative activities. The company issued new common stock and incurred a stock-based compensation expense during the period. Additionally, Imricor reported changes in fair value of option and warrant liabilities, impacting its other income and expenses. The financial report also discussed cash flows, highlighting net cash outflows from operating activities, and net cash inflows from investing activities mainly due to the maturity of marketable securities.